Results 131 to 140 of about 29,994,236 (203)

Breaking into HIV-1’s Epigenetic Vault: Cure Strategies to Eliminate the Viral Reservoir

Viruses
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that integrates into the host cell’s DNA as a provirus. Transcription from the provirus is regulated in large part by cellular proteins and epigenetic factors.
Joanna E. Jones, Chelsea E. Gunderson, Brian Wigdahl, Michael R. Nonnemacher   +3 more
doaj   +1 more source

Evaluation of HIV-1 latency reversal and antibody-dependent viral clearance by quantification of singly spliced HIV-1 vpu/env mRNA. [PDF]

J Virol, 2021
Gao H, Ozantürk AN, Wang Q, Harlan GH, Schmitz AJ, Presti RM, Deng K, Shan L.   +7 more
europepmc   +1 more source

24 Thalidomide reverses latency of HIV-1 provirus

Journal of Virus Eradication, 2016
S. Samer, T. Oshiro, T. Vergara, J. Gakinskas, S. Tenori, M.C. Sucupira, A. Duarte, R.S. Diaz   +7 more
openaire   +2 more sources

Reanalysis of Gene Expression Profiles of CD4+ T Cells Treated with HIV-1 Latency Reversal Agents. [PDF]

Microorganisms, 2020
Campos Coelho AV, Moura RR, Crovella S.
europepmc   +1 more source

The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal. [PDF]

J Biol Chem, 2020
Richard K, Schonhofer C, Giron LB, Rivera-Ortiz J, Read S, Kannan T, Kinloch NN, Shahid A, Feilcke R, Wappler S, Imming P, Harris M, Brumme ZL, Brockman MA, Mounzer K, Kossenkov AV, Abdel-Mohsen M, Andrae-Marobela K, Montaner LJ, Tietjen I.   +19 more
europepmc   +1 more source

Effective and targeted latency reversal in CD4⁺ T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection

To date, an affordable, effective treatment for an HIV-1 cure remains only a concept with most “latency reversal” agents (LRAs) lacking specificity for the latent HIV-1 reservoir and failing in early clinical trials.
Samiri Jamiru (18112371), Eric J. Arts (11846438), Tsigereda Biru (18112365), Jessica L. Prodger (9016712), Renata Ceccacci (18112362), Andrew D. Redd (6695216), Jamie F. S. Mann (16243997), Minh Ha Ngo (18112350), Ryan C. Y. Ho (18257394), Steven J. Reynolds (9176807), David H. Canaday (10431707), Paul Buule (18112377), Taddeo Kityamuweesi (18112374), Joshua Pankrac (18112353), Katja Klein (110677), Robert Assad (18112368), Aggrey Anok (9946237), Yue Li (102191), Thomas C. Quinn (6695213), Emmanuel Ndashimye (4591465), Rahul Pawa (18112359), Ronald M. Galiwango (9306104), Colin Kovacs (93789), Jeffrey M. Jacobson (10575533), Stephen Tomusange (17238265), Abayomi S. Olabode (12889292)   +25 more
core   +1 more source

Protocol for HIV-1 latency reversal using engineered bacteriophage T4 particles. [PDF]

STAR Protoc
Batra H, Rao VB.
europepmc   +1 more source

Metabolic reprogramming of CD4⁺ T cells by Zaprinast induces HIV-1 latency reversal ex vivo. [PDF]

Retrovirology
De Masson d'Autume V, LeDouce V, Dutilleul A, O'Reilly S, François N, Formiconi E, Angieladis M, Pilosio L, Bendoumou M, Leon AG, Alalwan D, Moore E, McGinty T, Valle-Casuso JC, Macken A, Rohr O, Van Lint C, Sáez-Cirión A, Cotter A, Feeney E, Mallon PWG, Gautier WV.   +21 more
europepmc   +1 more source

Optimisation of Smac mimetics as HIV-1 latency reversing agents

Journal of Virus Eradication, 2019
L. Pache, P. Teriete, M.D. Marsden, A.M. Spivak, D. Heimann, A.J. Portillo, V. Planelles, J.A. Zack, N.D.P. Cosford, S.K. Chanda   +9 more
openaire   +2 more sources

Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8⁺ T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal. [PDF]

J Virol, 2020
Mota TM, McCann CD, Danesh A, Huang SH, Magat DB, Ren Y, Leyre L, Bui TD, Rohwetter TM, Kovacs CM, Benko E, MacLaren L, Wimpelberg A, Cannon CM, Hardy WD, Safrit JT, Jones RB.   +16 more
europepmc   +1 more source